FilingsTodayTaekyung Chemical
At a glance
Taekyung Chemical filed 22 disclosures in the last 12 months, including 2 5% holder and 1 buyback. The most recent key filing was on Apr 2.
Revenue for 2025 was ₩61.3B, down 13.7% on 2024. Operating margin was 3.4% against 19.3% a year earlier. Debt was 30% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩26.1B and operating loss of ₩2.5B.
The 2025 annual report lists 103 employees with an average tenure of 9.8 years and average pay of ₩78.6M, #404 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩145M each on average. It paid ₩180 per common share in cash dividends, against ₩180 a year earlier (+0%). (주)태경비케이 and related parties held 58.67% at year end.
From the 2025 annual report
Staff: 103 (92 men, 11 women), of whom 15 on fixed-term contracts. Total pay for the year: ₩8.1B. Directors and auditors: 4, paid ₩580M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩180 | ₩180 | ₩200 |
| Payout ratio | 23.9% | 16.2% | 13.1% |
| Yield (as filed) | 2.20% | 1.60% | 1.50% |
| Total cash dividends | ₩2.1B | ₩2B | ₩2.3B |
Largest shareholder
(주)태경비케이 holds 40.01%; with 3 related parties the group holds 58.67% of common shares at year end (from 56.36% at the start of the year).
Auditor: 삼일회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.